Clinical studies, with a distinct focus on treatment resistant depression, play a crucial role in evaluating the safety and effectiveness of novel treatments. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption.

The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.

Inclusion Criteria:

• Diagnosis of treatment resistant depression
• Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
• No prior treatment for treatment resistant depression

Exclusion Criteria:

• Enrolled in another research study
• Inability to provide written informed consent
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Treatment resistant depression patients who are actively considering enrolling in a clinical trial for the said condition, but have not yet completed enrollment and randomization phases.